GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Emergent BioSolutions Inc (NYSE:EBS) » Definitions » Shiller PE Ratio

Emergent BioSolutions (Emergent BioSolutions) Shiller PE Ratio : 65.00 (As of Apr. 25, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Emergent BioSolutions Shiller PE Ratio?

As of today (2024-04-25), Emergent BioSolutions's current share price is $1.95. Emergent BioSolutions's E10 for the quarter that ended in Dec. 2023 was $0.03. Emergent BioSolutions's Shiller PE Ratio for today is 65.00.

The historical rank and industry rank for Emergent BioSolutions's Shiller PE Ratio or its related term are showing as below:

EBS' s Shiller PE Ratio Range Over the Past 10 Years
Min: 4.53   Med: 33.04   Max: 113
Current: 65

During the past years, Emergent BioSolutions's highest Shiller PE Ratio was 113.00. The lowest was 4.53. And the median was 33.04.

EBS's Shiller PE Ratio is ranked worse than
88.33% of 514 companies
in the Drug Manufacturers industry
Industry Median: 24.47 vs EBS: 65.00

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Emergent BioSolutions's adjusted earnings per share data for the three months ended in Dec. 2023 was $-0.880. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $0.03 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Emergent BioSolutions Shiller PE Ratio Historical Data

The historical data trend for Emergent BioSolutions's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Emergent BioSolutions Shiller PE Ratio Chart

Emergent BioSolutions Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 47.36 58.45 21.77 7.51 76.85

Emergent BioSolutions Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.51 8.21 10.17 19.56 76.85

Competitive Comparison of Emergent BioSolutions's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Emergent BioSolutions's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Emergent BioSolutions's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Emergent BioSolutions's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Emergent BioSolutions's Shiller PE Ratio falls into.



Emergent BioSolutions Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Emergent BioSolutions's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=1.95/0.03
=65.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emergent BioSolutions's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Emergent BioSolutions's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.88/129.4194*129.4194
=-0.880

Current CPI (Dec. 2023) = 129.4194.

Emergent BioSolutions Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -0.550 99.695 -0.714
201406 0.130 100.560 0.167
201409 0.490 100.428 0.631
201412 0.660 99.070 0.862
201503 -0.570 99.621 -0.740
201506 0.320 100.684 0.411
201509 0.790 100.392 1.018
201512 0.710 99.792 0.921
201603 0.100 100.470 0.129
201606 -0.270 101.688 -0.344
201609 0.450 101.861 0.572
201612 0.670 101.863 0.851
201703 0.230 102.862 0.289
201706 0.110 103.349 0.138
201709 0.680 104.136 0.845
201712 0.670 104.011 0.834
201803 -0.100 105.290 -0.123
201806 0.980 106.317 1.193
201809 0.410 106.507 0.498
201812 -0.070 105.998 -0.085
201903 -0.510 107.251 -0.615
201906 -0.180 108.070 -0.216
201909 0.830 108.329 0.992
201912 0.890 108.420 1.062
202003 -0.240 108.902 -0.285
202006 1.730 108.767 2.058
202009 0.730 109.815 0.860
202012 3.440 109.897 4.051
202103 1.280 111.754 1.482
202106 0.090 114.631 0.102
202109 -0.610 115.734 -0.682
202112 3.500 117.630 3.851
202203 -0.070 121.301 -0.075
202206 -1.130 125.017 -1.170
202209 -1.750 125.227 -1.809
202212 -1.760 125.222 -1.819
202303 -3.650 127.348 -3.709
202306 -5.150 128.729 -5.178
202309 -5.080 129.860 -5.063
202312 -0.880 129.419 -0.880

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Emergent BioSolutions  (NYSE:EBS) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Emergent BioSolutions Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Emergent BioSolutions's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Emergent BioSolutions (Emergent BioSolutions) Business Description

Traded in Other Exchanges
Address
400 Professional Drive, Suite 400, Gaithersburg, MD, USA, 20879
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company has four main units: vaccines, which produces specialty vaccines for public health threats; devices, such as nasal sprays, skin lotions, and injections; therapeutics, which includes antibody-based treatments; and contract development and manufacturing, which brings treatments to market through collaboration with the pharmaceutical and biotechnology industries and the United States government. Most revenue comes from U.S. government purchases of vaccines, devices, and therapeutic products. The company operates in two reportable segments; the Products Segment and the Services Segment.
Executives
Neal Franklin Fowler director C/O EMERGENT BIOSOLUTIONS INC., 400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879
Donald W Degolyer director 400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879
William Hartzel officer: SVP, Bioservices 400 PROFESSIONAL DRIVE, STE. 400, GAITHERSBURG MD 20879
Miller H Haywood Iii officer: Interim CEO EMERGENT BIOSOLUTIONS INC., 400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879
Kathryn C Zoon director 400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879
Paul Anthony Williams officer: SVP, Products Business 400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879
Ronald Richard director 2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
Sujata Tyagi Dayal director C/O BIOMET, INC., P.O. BOX 587, WARSAW IN 46581-0587
Keith Katkin director C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Glessner Coleen officer: EVP, Quality & Ethics, and CPL 400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879
Jennifer Lynne Fox officer: EVP, Ext Aff, GC, Corp Sec 400 PROFESSIONAL DRIVE, GAITHERSBURG MD 20879
Richard S Lindahl officer: EVP, Chief Financial Officer NEXTEL, 2001 EDMUND HALLEY DR, RESTON VA 20191
Sue Bailey director 400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20850
Adam Havey officer: EVP, BioDefense Division 2273 RESEARCH BLVD SUITE 400, ROCKVILLE MD 20853
Robert Kramer officer: Interim, EVP, BioSciences 2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850

Emergent BioSolutions (Emergent BioSolutions) Headlines

From GuruFocus

Emergent BioSolutions to Participate in Investor Conferences

By PurpleRose PurpleRose 08-10-2022